Stage‐Dependent Changes in Kynurenine Pathway Enzyme Expression Suggest Immune‐Related Involvement in Bladder Cancer Progression
International Journal of Urology · 2026-05 · 33 (5)
DOI: 10.1111/iju.70491 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Urology, online erschienen am 07.05.2026. Verfasst von Douglas Edgard Lemes und 7 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Innovation and Biotechnology Laboratory, Postgraduate Program in Medicine, Universidade Nove de Julho (Uninove), São Paulo, SP, Brazil. Hauptthemen laut MEDLINE: Kynurenine, Urinary Bladder Neoplasms, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Fundação de Amparo à Pesquisa do Estado de São Paulo, Conselho Nacional de Desenvolvimento Científico e Tecnológico.
Abstract (Originalsprache)
L‐tryptophan (Trp) metabolism through the L‐kynurenine (Kyn) pathway contributes to immune escape in neoplasms, including bladder cancer (BC). Indoleamine 2,3‐dioxygenase‐1 (IDO1) is a key enzyme, and its catabolites—Kyn, 3‐hydroxykynurenine (3HK), and 3‐hydroxyanthranilate (3HAA)—depend on other enzymes and play a crucial role in immunomodulation.
Objectives
We investigated the association between Kyn pathway enzyme expression and BC prognostic factors.
Methods
Data from 165 bc patients in the GEO DataSets were analyzed, comparing staging, tumor grade, progression, and recurrence with the expression of IDO1, arylformamidase (AFMID), kynurenine–oxoglutarate transaminase (KAT), kynureninase (KYNU), kynurenine 3‐monooxygenase (KMO), 3‐hydroxyanthranilate 3,4‐dioxygenase (HAAO), and aminocarboxymuconate‐semialdehyde decarboxylase (ACMSD). Predictive genes were further evaluated in RT4 (low‐grade, non‐invasive) and T24 (high‐grade, invasive) BC cells treated with IFN‐gamma and the IDO1 inhibitor INCB024360. Trp catabolites were quantified in the supernatant.
Results
Enzyme expression varied widely, especially for IDO1, AFMID, KAT, KMO, and KYNU. IDO1 correlated positively with KMO and negatively with KAT. High IDO1 and KMO levels were linked to advanced‐stage disease, while KAT and KYNU were associated with earlier stages and lower tumor grade. RT4 and T24 cells showed distinct basal enzyme expression, with T24 cells being more responsive to IFN‐gamma, increasing IDO1 and KYNU while decreasing KAT and KMO. These effects were inhibited by INCB024360. High Trp consumption increased Kyn and 3HAA but not 3HK.
Conclusions
Kyn pathway enzyme expression varies with disease progression and may indicate immune activity by influencing tumor microenvironment catabolites. BC cell sensitivity to immune stimuli differs, potentially shaping distinct immune escape mechanisms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Molecular Innovation and Biotechnology Laboratory, Postgraduate Program in Medicine, Universidade Nove de Julho (Uninove), São Paulo, SP, Brazil.
- Vaccine Development Laboratory, Department of Microbiology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, SP, Brazil.
- Vaccine Development Laboratory, Butantan Institute, São Paulo, SP, Brazil.
- Thyroid Diseases Center, Laboratory of Molecular and Translational Endocrinology, Division of Endocrinology, Department of Medicine, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, SP, Brazil.
- Urology Department, LIM/55 - Laboratory of urology, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Universidade de São Paulo, Instituto do Câncer do Estado de São Paulo, São Paulo, SP, Braz…
ORCID-Profile: Douglas Edgard Lemes, Aline Áurea de Souza Santos, Jéssica Lopes de Oliveira, Henrique Roman-Ramos, Ana Carolina Ramos Moreno, Cleber Pinto Camacho, José Pontes-Junior, Humberto Dellê
Förderung
- Fundação de Amparo à Pesquisa do Estado de São Paulo
- Conselho Nacional de Desenvolvimento Científico e Tecnológico
Zitieren
APA
Lemes, D. E., Santos, A. Á. S., de Oliveira, J. L., Roman-Ramos, H., Moreno, A. C. R., Camacho, C. P., Pontes-Junior, J., & Dellê, H. (2026). Stage‐Dependent Changes in Kynurenine Pathway Enzyme Expression Suggest Immune‐Related Involvement in Bladder Cancer Progression. International Journal of Urology, 33(5). https://doi.org/10.1111/iju.70491
Vancouver
Lemes DE, Santos AÁS, de Oliveira JL, Roman-Ramos H, Moreno ACR, Camacho CP, et al. Stage‐Dependent Changes in Kynurenine Pathway Enzyme Expression Suggest Immune‐Related Involvement in Bladder Cancer Progression. International Journal of Urology. 2026;33(5). doi:10.1111/iju.70491
BibTeX
@article{Lemes2026,
author = {Lemes, Douglas Edgard and Santos, Aline Áurea de Souza and de Oliveira, Jéssica Lopes and Roman-Ramos, Henrique and Moreno, Ana Carolina Ramos and Camacho, Cleber Pinto and Pontes-Junior, José and Dellê, Humberto},
title = {Stage‐Dependent Changes in Kynurenine Pathway Enzyme Expression Suggest Immune‐Related Involvement in Bladder Cancer Progression},
journal = {International Journal of Urology},
year = {2026},
volume = {33},
number = {5},
doi = {10.1111/iju.70491}
}
EUVIMED